3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
8
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
3
Plasma cell
2
Dermatologic
2
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Conditions
Mesothelioma
1
Lung Neoplasms
1
Interventions
Carboplatin
10
Cisplatin
7
Pemetrexed
6
Vincristine
5
Nivolumab
5
Etoposide
4
Topotecan
3
Specimen Handling
3
Ipilimumab
3
Injections
3
Doxorubicin
3
Talc
2
Radiotherapy
2
Paclitaxel
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Filgrastim
2
Drug Therapy
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
sintilimab
1
ranpirnase
1
raltitrexed
1
pertuzumab
1
pembrolizumab
1
onartuzumab
1
iniparib
1
durvalumab
1
dostarlimab
1
crofelemer
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Vorinostat
×
Other solid neoplasm
×
Clear all
NCT00128102
2020-10-26
MK-0683-014
Merck Sharp & Dohme LLC
Phase 3
Completed
661 enrolled
18 charts